Novavax clinical trials we track

Check company identity source

Phase 3 9 trials

TrialDrugs studiedStatusPrimary completion
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineNCT06291857CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Fluzone High Dose, Novavax COVID-19 Vaccine, tNIV VaccineCompleted2025-12-24Actual
A Strain Change Study for SARS-CoV-2 rS VaccinesNCT06409663NVX-CoV2705 VaccineCompleted2024-10-15Actual
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesNCT05973006NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)Completed2024-04-01Actual
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNCT05875701NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M AdjuvantCompleted2023-11-11Actual
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2NCT04611802SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)Completed2023-04-10Actual
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNCT05463068NVX-Cov2373Completed2022-08-17Actual
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesNCT05372588NVX-CoV2373 + NVX-CoV2515, NVX-CoV2373 + NVX-CoV2540, NVX-CoV2515, NVX-CoV2540 and 1 moreCompleted2022-07-17Actual
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomNCT04583995Licensed seasonal influenza vaccine, SARS-CoV-2 rS/Matrix M1-AdjuvantCompleted2022-03-29Actual
A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal ImmunizationNCT02624947Formulation buffer, RSV F vaccine with adjuvantCompleted2018-12-28Actual

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

CompletedPrimary completion: 2023-04-10 · Actual
Trial details
Registry ID
NCT04611802
Drugs studied
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)

Phase 2 / 3 3 trials

Phase 2 1 trial

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters